This study provides the first evidence of vaccine protection in younger children (5-11) and underscores the benefits of COVID ...
German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...
On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...
Hosted on MSN2d
Should Kids Get the COVID-19 Vaccine?The Centers for Disease Control and Prevention (CDC) recommends the Moderna and Pfizer-BioNTech COVID-19 vaccines for kids as ...
Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
The Centers for Disease Control and Prevention's (CDC's) 2024-2025 COVID-19 vaccine immunization schedule advises, in the ...
Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...
Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback